One Solution Repairing All Nerves
Maxonis is a start-up biotech company developing an innovative, proprietary biodegradable hydrogel—AGRG (Antigliotic Guiding Regenerative Gel)—designed to promote nerve regeneration.
Maxonis AGRG offers a revolutionary nerve regeneration solution for treating nerve injuries in the peripheral and central nervous systems.
Our mission is to provide hope to those whose quality of life has been severely impacted by nerve injuries.
Revolutionizing Nerve Repair
Nerve Injury is a worldwide growing phenomenon with limited solutions. The high cost of supporting patients and improving their quality of life is driving the market to continuously seek for nerve regenerating solutions.
Peripheral Nerve injuries (“PNI”)
Approx. 2.3 million people undergo peripheral nerve repair operations every year.
Maxonis AGRG-based technology offer a safe treatment for PNI patients with a large nerve gap that have limited treatment options.
In pre-clinical trials, our AGRG-based treatment demonstrated a significant improvement in various parameters in comparison to commercially available products.
Our AGRG-based treatment offers a simple procedure that minimizes the surgical risks.
Spinal Cord injuries (“SCI”)
Today there are approx. 7M people living with chronic spinal cord injuries worldwide; Approx. 500,000 are suffering from acute SCI every year.
Unfortunately, no treatment can reverse or repair spinal cord damage.
In pre-clinical trials, our AGRG-based treatment has demonstrated a significant improvement in regenerating axonal growth for SCI, promising a meaningful enhancement in patients' quality of life.
"The Nerve Repair and Regeneration Market Size is anticipated to witness significant expansion, reaching around USD 32.4 Billion by 2033. This marks a considerable rise from its 2023 value of USD 9.2 Billion. The projected growth is set to occur at a Compound Annual Growth Rate (CAGR) of 13.4% over the forecast period from 2024 to 2033.”
